The publication OncLive convened a panel of experts to break down the SCLC news from the ASCO conference held in June 2025. Panelists discussed strategies for treating limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) small cell lung cancer, including:
- Integration of durvalumab in LS-SCLC
- New first-line chemoimmunotherapy regimens in ES-SCLC
- Maintenance approaches such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305)
- The promising future role of agents including T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304)